[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cied-related-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cied-related-infections":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100548211","infectious-disease-registry-biobank-100548211",false,"NCT06418048","INfectious DIsease REgistry BIObank","Prospective Registry and Biobank of Patients With Infectious Diseases","INDI-REBIO","Inclusion Criteria:\n\n* Patients with clinically suspected or microbiologically documented infectious diseases (bacterial, viral, fungal or parasitic);\n* At least 18 years of age or older;\n* Able to provide informed consent;\n* Participants who are unable to understand the study protocol or are unable to give informed consent, but have a legal representative\n\nExclusion Criteria:\n\n\\- Participants who are unable to understand the study protocol or are unable to give informed consent, and have no legal representative.","ALL","18 Years",{"count":20,"type":21},10000,"ESTIMATED","20 Years","OBSERVATIONAL","Prospective observational study designed to describe the clinical, laboratory, imaging, microbiological characteristics and treatment of specific infectious diseases, with the addition of a dedicated biobank.",[26,27,28,29,30,31,32],"Bloodstream Infections","Central Nervous System Infections","Bone and Joint Infections","Endovascular Infections","Infective Endocarditis","CIED-related Infections","Vertebral Osteomyelitis","RECRUITING","2026-04-15",{"date":36,"type":37},"2026-04-20","ACTUAL",{"date":39,"type":37},"2024-02-01",{"date":41,"type":21},"2044-07-31",{"name":43,"class":44},"IRCCS San Raffaele","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100609149","cied-implantation-technique-at-assiut-university-heart-hospital-in-relation-to-esc-guidelines-100609149","NCT07210801","CIED Implantation Technique at Assiut University Heart Hospital in Relation to ESC Guidelines","Magnitude of Alignment With ESC Guidelines in Implantation Techniques of Cardiac Implantable Electronic Devices and Its Impact on Clinical Outcomes","Inclusion Criteria:\n\n* All addult patients (≥18 years) referred foran indicatedCIED implantation at Assiut University Heart Hospital\n\nExclusion Criteria:\n\n* Previous implantation of CIED implantation\n* General contraindications of CIED\n* Patient refusal",{"count":54,"type":21},200,"30 Days","This prospective observational cohort study will evaluate the extent to which cardiac implantable electronic device (CIED) implantation techniques at Assiut University Heart Hospital (AUHH) align with the evidence-based recommendations of the European Society of Cardiology (ESC).",[31,58],"CIED Implantation","NOT_YET_RECRUITING","2025-10-02",{"date":62,"type":37},"2025-10-07",{"date":64,"type":21},"2025-10-01",{"date":66,"type":21},"2027-11-01",{"name":68,"class":44},"Assiut University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100605129","antimicrobial-strategy-for-device-implantation-100605129","NCT07158502","Antimicrobial Strategy for Device Implantation","Prevention of Infections Associated With Implantable Cardiac Devices","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinical indication for CIED implantation or generator replacement\n* Signed informed consent to participate in the study\n\nExclusion Criteria:\n\n* Known allergy to taurolidine or any of the excipients\n* Severe immunodeficiency status (e.g., patients undergoing chemotherapy, with AIDS, or immunosuppressed following organ transplantation)\n* Life expectancy \\\u003C 12 months due to severe comorbidities (e.g., metastatic cancer, end-stage organ failure)\n* Pregnant or breastfeeding women",{"count":77,"type":21},1000,"Infections associated with cardiovascular implantable electronic devices (CIEDs) represent one of the major postoperative complications in interventional cardiology. These infections-including lead-related endocarditis, subcutaneous pocket infections, and sepsis-are characterized by high rates of morbidity, mortality, and healthcare costs. According to current epidemiological data, the incidence of CIED-related infections is estimated to be around 0.5-2% within the first 12 months and may rise to 5% over long-term follow-up. These infections are associated with a mortality rate of up to 34% and often require device explantation and prolonged antibiotic therapy.\n\nTauroPace™ is an antimicrobial solution based on taurolidine, a broad-spectrum, non-antibiotic agent that acts by disrupting bacterial biofilms and preventing microbial colonization. Taurolidine has a favorable safety profile, does not induce antibiotic resistance, and is already approved in Europe as a CE-marked medical device (Directive 93\u002F42\u002FEEC). The application of TauroPace™ to the surface of CIEDs prior to implantation may significantly reduce the incidence of infections compared to the current standard, which consists of irrigating the device pocket with sterile saline solution.\n\nThe aim of this study is to rigorously and systematically evaluate the effectiveness of TauroPace™ compared to standard clinical practice.",[31],"2025-08-28",{"date":82,"type":37},"2025-09-05",{"date":84,"type":21},"2025-09-01",{"date":86,"type":21},"2027-12-31",{"name":88,"class":44},"University of Calabria"]